The Priority Review

Tag

Boehringer Ingelheim

7 stories

Stories

  1. Clinical trials

    Boehringer Ingelheim registers Phase 3 safety rollover trial of obrixtamig in advanced cancer

    The study, first posted on ClinicalTrials.gov on November 10, 2026, plans to enroll 68 participants and begin in March 2027. It plans to find out how well participants who received obrixtamig in a previous study tolerate the drug.

  2. Clinical trials

    Survodutide shows no increased cardiovascular risk in obesity trial

    The authors reported that in the SYNCHRONIZE-CVOT phase 3 trial, 136 of 3671 participants receiving survodutide experienced the primary composite endpoint versus 76 of 1836 receiving placebo (HR 0·89 [95% CI 0·67-1·18]). Gastrointestinal adverse events were more frequent with survodutide, with nausea in 48·0%-49·0% and vomiting in 31·7%-34·0% of participants.

  3. Clinical trials

    Boehringer Ingelheim registers Phase 3 study of verducatib in bronchiectasis

    The study, NCT07915219, plans to enroll 1500 participants and begin on January 11, 2027, to evaluate long-term safety and efficacy of verducatib in patients with bronchiectasis. Participants can stay in the study for up to 1 year and 9 months, with primary completion projected for July 31, 2029.

  4. Clinical trials

    Boehringer Ingelheim registers Phase III trial of verducatib in COPD

    The AIRWARD Study plans to enroll 1800 participants with COPD and plans to start on March 10, 2027. It evaluates whether verducatib reduces flare-ups and improves lung function compared with placebo over up to 1.5 years.

  5. Clinical trials

    Boehringer Ingelheim posts results of 1-yr Tiotropium/Salmeterol study in COPD

    Results for the 220-participant, Phase 3, randomized, triple-masked study were posted on October 29, 2026. The study compared FDC tiotropium/salmeterol with single agents and assessed FEV1, dyspnoea, health status and exacerbations.

  6. Clinical trials

    Boehringer Ingelheim registers Phase 3b trial of Survodutide in MASLD

    This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 600 participants and planned start date is October 23, 2026.

  7. Clinical trials

    Boehringer Ingelheim registers study of survodutide in overweight or obesity without diabetes

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The Phase IIIb, open-label study plans to enroll 350 participants, with a planned start date of November 7, 2026 and a primary completion date of June 25, 2028.